natgillin/translations-raw huggingface dataset:
However, when the metal ions are immobilized, at least three limiting factors come into play, namely reduced number of available coordination sites on the metal, restricted accessibility of the tethered metal to the binding sites on the protein, and, depending upon the characteristics of the resin, limited protein access to the immobilized metal ion. 
Međutim, kada su metalni ioni imobilizirani najmanje tri ograničavajuća čimbenika su važna za vezanje, a to su smanjeni broj slobodnih koordinacijskih mjesta na metalu, smanjena pristupačnost tretiranog metala veznom mjestu na proteinu i ovisno o karakteristikama nosača ograničeni pristup proteinu imobiliziranim metalnim ionima.
Use of the process according to claim 31 or 32, in a furnace sorbent injection method, in spray drying, or in fire fighting. 
Uporaba postupka prema zahtjevu 31 1li 32, naznačena time da se koristi u postupku injektiranja sorbenta u peć, kod sušenja raspršivanjem, ili za gašenje požara.
The method according to statement 1, wherein the seal has a seal elongation at failure of about 25% to about 100%, preferably the seal has a seal elongation at failure of about 30% to about 90%, more preferably the seal has a seal elongation at failure of about 35% to about 80%, even more preferably the seal has a seal elongation at failure of about 35% to about 55%, as measured in accordance with ASTM F88/F88M-09. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da brtva ima vrijednost elongacije pri prekidu od oko 25 % do oko 100 %, poželjno je da brtva ima vrijednost elongacije pri prekidu od oko 30% do oko 90%, a osobito da brtva ima vrijednost elongacije pri prekidu od oko 35% do oko 80%, izmjereno u skladu s ASTM F88/F88M-09.
The ligand-drug conjugate of any one of claims 1 to 5 for use in the treatment of a CD19-associated disorder in a mammalian subject, for example a CD19 expressing cancer, chronic leukemia, lymphoma, or multiple myeloma; for example B type acute lymphoblastic leukemia, chronic myelocytic leukemia, chronic lymphocytic leukemia, non-Hodgkin lymphoma and Hodgkin lymphoma, B cell lymphoma, or diffuse large B-cell lymphoma; said treatment comprising administering a pharmaceutical composition comprising the ligand drug conjugate and a pharmaceutically acceptable carrier or excipient in an amount effective to treat the disorder in the mammalian subject. 
Konjugat ligand-lijek prema bilo kojem od zahtjeva 1 do 5 naznačen time da je za uporabu za liječenje poremećaja povezanog s CD19 kod subjekta koji je sisavac, na primjer raka koji izražava CD19, kronične leukemije, limfoma ili multiplog mijeloma; na primjer, akutne limfoblastične leukemije tipa B, Hodgkinovog mijelocitne leukemije, kronične limfocitne leukemije, ne-Hodgkinovog limfoma i Hodgkinovog limfoma, limfoma B-stanica, ili difuznog limfoma velikih B-stanica; te se navedeno liječenje sastoji od primjene farmaceutskog pripravka koji sadrži konjugat lijek-ligand 1 farmaceutski prihvatljiv nosač ili pomoćnu tvar u količini koja je učinkovita za liječenje poremećaja kod subjekta koji je sisavac.
A process according to any preceding para, wherein the coating additionally comprises a second compound selected from one or more fatty acids and one or more salts of a fatty acid, and combinations thereof.and. A functional filler comprising: 
Postupak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što obloga dodatno sadrži drugi spoj, kojeg se bira između jedne ili više masnih kiselina 1 jedne ili više soli masnih kiselina, te njihovih kombinacija.
The cores so obtained are then film-coated with a hydroalcoholic dispersion of acrylic and methacrylic acid esters, titanium dioxide, talcum and triethyl citrate, which confers on the product resistance to disintegration in a strongly acidic environment, simulating the environment of the stomach and the small intestine. 
Tako dobivene jezgre obložene su filmom hidroalkoholnim raspršenjem estera akrilnih i metakrilnih kiseline, titan dioksida, talka i trietil citrata, što produktu daje otpornost na razgradnju u jakom kiselinskom okolišu kao što je to okoliš želuca i tankog crijeva.
Such liquid forms include solutions, suspensions, and emulsions. 
Takvi tekući oblici obuhvaćaju otopine, suspenzije i emulzije.
expanding the isolated DPFs in monolayer culture without collagen coating, wherein said DPFs are passaged at least once, 
(c) ekspandiranja izoliranih DPF-ova u jednoslojnoj kulturi bez kolagenske prevlake, pri čemu su navedeni DPF- ovi barem jednom pomaknuti,
The aqueous pharmaceutical suspension according to claim 7, wherein the hydrocolloid gum is xanthan gum. 
Vodena farmaceutska suspenzija u skladu s patentnim zahtjevom 7, naznačena time što hidrokoloidna guma je ksantanska guma.
g of donepezil hydrochloride hydrate, 1587 g of lactose monohydrate, 857 g of pregelatinised starch and 429 g of corn starch were homogenised in a biconic mixer for 10 minutes at 26 rpm. 
Primjer 1: Filmom obložene tablete dobivene postupkom direktne kompresije 111,8 g donepezil hidroklorid hidrata, 1587 g monohidratne laktoza, 857 g preželatiniziranog škroba i 429 g kukuruznog škroba homogenizirano je u bikoničnom mikseru tijekom 10 minuta pri 26 okretaja u minuti.
is a hydrogen atom; and 
R* predstavlja atom vodika; i
a domain from a Mycobacterium polypeptide, which is Ag85B or Ag85A which is capable of eliciting an immune response, and 
(a) domenu iz polipeptida mikobakterije, koja je Ag85B ili Ag85A, koja može potaknuti imuni odgovor, i
A method according to any preceding claim, wherein the mineral fibres are provided in the form of an uncured web containing wet binder. 
Postupak sukladno bilo kojem prethodnom patentnom zahtjevu, pri čemu su mineralna vlakna dobivena u obliku neočvrsle mreže koja sadrži vlažno vezivno sredstvo.
The use according to claims 12 or 13, characterized in that the pain is selected from inflammatory pain, neuropathic pain, acute pain, chronic pain, visceral pain, migraine pain, and cancer pain. 
Uporaba prema zahtjevima 12 ili 13, naznačena time da bol je odabrana od upalne boli, neuropatske boli, akutne boli, kronične boli, visceralne boli, boli zbog migrene, te boli zbog karcinoma.
Antibody fragment according to claims 3 and 4, wherein the humanized light chain variable domain comprises the complementarity determining regions (CDRs) having the sequences set forth in SEQ ID No. 
Fragment protutijela u skladu s patentnim zahtjevima 3 i 4, naznačen time što varijabilna domena humaniziranog lakog lanca sadrži područja za određivanje komplementarnosti (CDR) sa sljedovima iznijetim u SEQ ID No.
the alkylsulfonyl, alkenylsulfonyl, and alkynylsulfonyl optionally are substituted with one or more substituents independently selected from the group consisting of carboxy, hydroxy, halo, amino, nitro, azido, oxo, aminosulfonyl, alkyloxycarbonyl, alkenyloxycarbonyl, alkynyloxycarbonyl, alkylcarbonyloxy, alkenylcarbonyloxy, alkynylcarbonyloxy, alkyloxy, alkenyloxy, alkynyloxy, carbocyclyl, heterocyclyl, cyano, and aminocarbonyl, wherein: 
alkilsulfonil je opcijski supstituiran s jednim ili dva supstituenta neovisno odabranima iz skupine koju sačinjavaju karboksi, hidroksi, halo, amino, nitro, okso, aminosulfonil, alkiloksikarbonil, alkilkarboniloksi, alkiloksi, karbociklil, heterociklil, cijano i aminokarbonil; i
A method for preparing a diol, characterized in that the method uses a sugar and hydrogen as starting materials, which are brought into contact with a catalyst in water to prepare a diol; the catalyst used is a composite catalyst, consisting of a main catalyst and a cocatalyst, 
Postupak za pripremu diola, naznačen time što postupak koristi šećer i vodik kao polazišne materijale koji se dovode u kontakt s katalizatorom u vodi za pripremu diola; korišteni katalizator je kompozitni katalizator, koji se sastoji od glavnog katalizatora i kokatalizatora, pri čemu glavni katalizator je u vodi netopiva legura otporna na kiseline koja se sastoji od nikla, jednog ili više rijetkih zemljanih elemenata, kositar i aluminij i izborno i) volfram, ii) volfram i molibden, ili iii) volfram, molibden i bor ili fosfor;
The compound for the use of claim 1 wherein X is H and Y is OR7; or preferably wherein Y is OR7, and R7 is cladinosyl. 
Spoj za uporabu prema zahtjevu 1 gdje X je Hi Y je OR", gdje R/ je kladinozil.
A process according to Claim 1, wherein the acylating agent is present in an amount of from 1 molar equivalents to 1.5 molar equivalents, based on the molar equivalents of 8-hydroxy-(1 H)-quinolin-2-one. 
Postupak prema zahtjevu 1, naznačen time, da je acilatni agens prisutan u količini od 1 molarnog ekvivalenta do 1,5 molarnih ekvivalenata, bazirano na molarnim ekvivalentima od 8-hidroksi-(1H)-kinolin-2-ona.
a drive mechanism for rotating said first ring member; and a coupling mechanism for releasably coupling said first ring member to said second ring member, to allow said first and second ring members to rotate cooperatively when coupled and to allow independent rotating of said first ring member when not coupled; 
Brojač kao što je navedeno u zahtjevu 1 dalje sadržeći mehanizam sparivanja (700) za odvojivo sparivanje navedenog prvog prstenastog elementa (201) s navedenim drugim prstenastim elementom (202, 1510), kako bi se omogućilo navedenim prvom i drugom prstenastom elementu da kooperativno rotiraju kad spareni te kako bi se omogućilo samostalno rotiranje navedenog prvog prstenastog elementa kad nije sparen.
Thus, the present invention provides processes useful for improving the solubility of ET-743 in the bulking solution that comprise dissolving ET-743 in an acidic medium, mixing the medium with ET-743 with other components of the bulking solution, and, optionally, adjusting the pH. 
Prema tome, predstavljeni izum daje postupke korisne za poboljšanje topljivosti ET-743 u otopini za punjenje koji obuhvaćaju otapanje ET-743 u kiselom mediju, miješanje medija sa ET-743 sa drugim komponentama otopine za punjenje, i izborno, podešavanje pH vrijednosti.
The assay plate is sealed with Topseal-S™ and incubated in the dark at room temperature on a shaker for 45 minutes. 
Pokusna pločica je začepljena s Topseal-S"" i inkubirana 45 minuta u mraku pri sobnoj temperaturi na mućkalici.
reacting with cyclopropylamine to form reacting the product of step (a) with to form 
(b) reakciji produkta iz koraka (a) s kako bi se dobilo
a compound of Formula (I) having the structure: or 
spoj sa formulom (I) koje ima strukturu: [image] ili
Acetyl-leucine, or a pharmaceutically acceptable salt thereof, for use in a method according to any of embodiments 1-9, wherein the method comprises administering a therapeutically effective amount of the acetyl-leucine to the subject in need thereof for a duration chosen from at least about 3 months, at least about 6 months, at least about 1 year, at least about 2 years, and at least about 5 years. 
Acetil-leucin, ili njegova farmaceutski prihvatljiva sol, za uporabu prema bilo kojem od zahtjeva 1-4, naznačen time što uporaba obuhvaća davanje terapeutski učinkovite količine acetil-leucina subjektu kojemu je to potrebno u trajanju odabranom od najmanje oko 3 mjeseca, najmanje oko 6 mjeseci, najmanje oko 1 godine, najmanje oko 2 godine, te najmanje oko 5 godina.
a combination thereof, characterised in that said additional component contains a determined amount of said lysine and/or tryptophan such that by adding said additional component to said protein component said composition provides a desired essential amino acid units combination where on the whole said lysine and tryptophan in said composition have a weight ratio set between 2,5 and 4,and in that said composition further contains a component selected from the group comprised of: 
- < njihovu kombinaciju, naznačeno time da spomenuta dodatna komponenta sadrži određenu količinu spomenutih lizina i/ili triptofana tako da se dodavanjem spomenute dodatne komponente spomenutoj proteinskoj komponenti spomenute kompozicije osigurava željena kombinacija esencijalnih aminokiselinskih jedinica, pri čemu u cjelini promatrano spomenuti lizin i triptofan u spomenutoj kompoziciji imaju težinski odnos koji se nalazi između 2,5 i 4, i time da spomenuta kompozicija dalje sadrži komponentu koja je izabrana iz grupe koja sadrži:
providing or generating at least one candidate sequence which consists of an amino acid sequence modified by substituting one or two amino acid residues to an original amino acid sequence, wherein the original amino acid sequence is selected from the group consisting of SEQ ID NOs: 30, 19, 22, 34, and 358; 
(1) osiguravanja najmanje jednog slijeda kandidata koji ima aminokiselinski slijed modificiran zamjenom jednog ili dva aminokiselinska ostatka u izvornom aminokiselinskom slijedu, gdje se izvorni aminokiselinski slijed se bira iz skupine koju čine SEQ ID NO:41, 44, 46, 48 1 78;
A compound for use as defined in claim 18, wherein the pain is inflammatory pain, neuropathic pain, pain associated with cancer, pain associated with surgery, or pain associated with bone fracture. 
Spoj za uporabu kako je definiran u zahtjevu 18, naznačen time da bol je upalna bol, neuropatska bol, bol povezana s rakom, bol povezana s operacijom, ili bol povezana s lomom kosti.
The method of claim 13, wherein the at least one heterologous antigen is selected from the group consisting of: an HIV antigen, an SIV antigen, a hepatitis B virus antigen, a hepatitis C virus antigen, a Clostridium tetani antigen, Mycobacterium tuberculosis antigen, and a plasmodium antigen. 
Vektor CMV, namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što se heterologni antigen bira iz skupine koju čine: antigen HIV gag, antigen HIV env, antigen HIV rev, antigen HIV tat, antigen HIV nef, antigen HIV pol, te antigen HIV int.
Compounds according to claim 1, wherein E represents a phenyl group, a pyridin-2-yl, a cyclohexyl group, a pyrazol-1-yl group, a cyclopentyl group, an indol-4-yl group, a cyclopropyl group, a pyridin-3-yl group, an indol-3-yl group, a naphth-1-yl group, an imidazol-4-yl group or a pyridin-4-yl group. 
Spojevi u skladu s patentnim zahtjevom 1, naznačeni time, da E predstavlja fenilnu skupinu, piridin-2-il, cikloheksilnu skupinu, pirazol-1-il skupinu, ciklopentilnu skupinu, indol-4-il skupinu, ciklopropilnu skupinu, piridin-3-il skupinu, indol-3-il skupinu, naft-1-il skupinu, imidazol-4-il skupinu ili piridin-4-il skupinu.
A method for bonding of a synthetic polymer nonwoven material with a synthetic polymer nonwoven material according to claim 1, comprising the steps, (i)- pretreating corresponding regions of one of the synthetic polymer nonwoven material by atmospheric pressure plasma, (ii)- optionally pretreating regions of another synthetic polymer nonwoven material by atmospheric pressure plasma, (iii)- applying adhesive or glue onto targeted regions of at least one of said synthetic polymer nonwoven materials, (iv)-joining said regions together. 
Metoda za vezivanje poliolefinskog netkanog materijala sa poliolefinskim netkanim materijalom prema patentnom zahtjevu 1, koja obuhvaća korake, (i)- tretiranja odgovarajućih regija jednog od poliolefinskog netkanog materijala pomoću plazme na atmosferskom pritisku, (1i)- opcionalnog tretiranja regija drugog poliolefinskog netkanog materijala pomoću plazme na atmosferskom pritisku, (11i)- nanošenja adheziva ili ljepila na ciljane regije najmanje jednog od navedenih poliolefinskih netkanih materijala, (iv)- spajanja navedenih regija zajedno.
Inhibition of dipeptidyl peptidase-IV (DP-IV), an enzyme that inactivates both glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide 1 (GLP-1), represents a novel approach to the treatment and prevention of Type 2 diabetes, also known as non-insulin dependent diabetes mellitus (NIDDM). 
Inhibicija dipeptidil peptidaze-IV (DP-N), enzima koji deaktivira kako inzulinotropni peptid (GIP) ovisan o glukozi, kao i glukagonu-slični peptid 1 (GLP-1), predstavlja inovativni pristup liječenju i prevenciji dijabetesa tipa 2, poznatog i kao inzulin neovisni dijabetes mellitus (NIDDM).
The processed food or feed commodity of claim 5, wherein said polynucleotide further comprises SEQ ID NO: 6 or SEQ ID NO: 7. A corn plant comprising the polynucleotide of SEQ ID NO: 2 or a complement thereof. 
Prerađena hrana ili stočna hrana prema jednom od zahtjeva 8 ili 9, pri čemu navedeni polinukleotid nadalje sadrži nukleotidnu sekvencu iz SEQ ID NO: 3, SEQ ID NO: 4, ili njihov komplement.
Further processes of chromatographic type are reported in the following patents: JP 61-291540 uses an absorbent resin composed of a non-polar porous polymer (styrene-divinylbenzene copolymer) and an eluent, containing a hydrophilic polar solvent, preferably methanol, suitably modified, to fraction the required polyunsaturated acid or its ester. 
Daljnji postupci kromatografskog tipa su opisani u sljedećim patentima: JP 61-291540 upotrebljava apsorpcijsku smolu sastavljenu od nepolarnog poroznog polimera (stiren-divinilbenzen kopolimer) i eluens, koji sadržava hidrofilno polarno otapalo, poželjno metanol, prikladno modificiranog, za frakcioniranje tražene polinezasićene kiseline ili njenog estera.
Consequently, upon hydrolysis of the carbonate linkage, the rapamycin will be released in its naturally-occurring configuration. 
Kao posljedica, nakon hidrolize karbonatne veze, rapamicin se oslobađa u svojoj prirodnoj konfiguraciji.
an antibody which is capable of binding an epitope of human IAPP, wherein the antibody or the IAPP binding fragment thereof comprises in its variable region the following six complementarity determining regions (CDRs): 
(b) antitijelo koje je sposobno vezati epitop humanog IAPP, pri čemu antitijelo ili njegov IAPP vezujući fragment sadržava u svojoj varijabilnoj regiji slijedećih šest regija za određivanje komplementarnosti (CDR):
In a preferred embodiment, the capture step is carried out by ion exchange chromatography. 
U poželjnoj izvedbi, korak lovljenja proteina provodi se s pomoću kromatografije izmjene iona.
The composition of claim 1, 2 or 3, wherein the amount of diesel and/or gasoline is in a range of from 13 - 17 vol.-% each. 
Izopropanol sukladno patentnom zahtjevu 1 pri čemu je količina dizelskog i/ili jeftinijeg benzinskog goriva u rasponu od 13 - 17 vol-% svaka.
To that end, a microencapsulated bacterial consortium has been developed for gluten degradation, comprising: a) three different strains of commercially available lactic acid bacteria; b) encapsulating agents; c) prebiotics; and d) trehalose; in combination with a proteolytic enzyme of bacterial origin and a proteolytic enzyme of fungal origin. 
HR P20190663 T1 PATENTNI ZAHTJEVI nos Mikroenkapsulirani bakterijski konzorcij, naznačen time što sadrži: (a) tri različita soja komercijalno dostupnih bakterija mliječne kiseline; b) agense za enkapsulaciju; c) prebiotike; 1 d) trehalozu; u kombinaciji s proteolitičkim enzimom bakterijskog porijekla i proteolitičkim enzimom gljivičnog porijekla.
Y is mesylate, tosylate, triflate or halogen, and A4b is absent or represents C1-C3alkylene, C1-C3alkenylene or a radical selected from the group consisting of —CH2NH—, —CH2O—, and —CH2S—, said radical being linked to G via the nitrogen, oxygen or sulfur atom; or when L1 is N(R5)E and E is an amino protecting group said protecting group is removed and the deprotected intermediate is reacted with a compound of formula III as defined above. 
Y je mesilat, tosilat, triflat ili halogen; i A4b je odsutan ili predstavlja C,-C3alkilen, C,-Czalkenilen ili skupinu koju se bira između -CH,NH-, 1 - CH>S-, gdje je navedena skupina vezana na G preko atoma dušika, kisika ili sumpora; ili kada je LI N(RSJE, a E je zaštitna skupina za amino, navedenu zaštitna skupina se uklanja, a međuprodukt s kojeg je skinuta zaštita reagira sa spojem formule III kao što je definirano gore.
reacting an intermediate (4a) with intermediate (4b) as outlined in the following reaction scheme: 
(6) reakciju intermedijera (4a) sa intermedijerom (4b) kako je navedeno u slijedećoj reakcijskoj shemi:
the composition comprises polysorbate-80; 
(v) farmaceutski sastav obuhvaća polisorbat-80;
The method according to claim 7, wherein the siRNA is administered for 5 to 15 days. 
7. < siRNK za primjenu prema prethodnom patentnom zahtjevu gdje spomenuta siRNK je administrirana lokalno na oko.
gas outlets (160) for leading the gas out of the chamber, 
- < ispuste plina (160) za izvođenje plina iz komore,
In some embodiments, the appropriate solvent is water. 
Postupak iz zahtjeva 26, naznačen time da je odgovarajuće otapalo voda.
A capsule according to claim 13, wherein the height of the further ridge is larger than the height of the at least one projection. 
Kapsula (2) prema zahtjevu 21, naznačena time, da je visina dodatnog grebena (40) veća od visine grebena (28.i).
A speech decoding device for decoding an encoded speech signal, the speech decoding device comprising: a processor configured to: 
Naprava za dekodiranje govora, namijenjena dekodiranju kodiranog govornog signala, naznačena time što se naprava za dekodiranje govora sastoji od:
(0-2) substituting X with PLG by reaction of a reagent PLG-H in the presence of a base, to obtain a compound of formula II' and 
o gdje X je Clili Br, (0-2) supstitucija X s PLG pomoću reakcije reagensa PLG-H u prisutnosti baze, kako bi se dobio spoj formule II'
A pharmaceutical composition according to any one of claims 1-28, wherein such single dose form is a tablet or capsule adapted for oral administration. 
Farmaceutska kompozicija prema bilo kojem od patentnih zahtjeva 1-31, naznačena time što je takav pojedinačni dozni oblik tableta ili kapsula prilagođena za oralnu primjenu.
Preparation of Filler Ingredients 
Priprava sastojaka za punjenje
or phenyl, wherein said phenyl is optionally substituted with R6; is 
GO m fenil, pri čemu je navedeni fenil proizvoljno sngstituiiran s R';
selecting a length of the curved blades to use by moving the blades linearly relative to the handle to an extended position or a non-extended position. 
(b) odabiru duljine zakrivljenih oštrica (28) radi upotrebe podešavanjem oštrica (28) u najmanju ruku ispruženom položaju ili neispruženom položaju.
The device (1) for overturning containers (2) according to claim 1, wherein the rotation actuator (3) is pneumatic. 
Uređaj (1) za okretanje spremnika (2) prema zahtjevu 1, naznačen time da je rotacijski pokretač (3) pneumatski.
The RNAi molecule according to [3], which consists of the nucleotide sequence represented by SEQ ID NO: 8. 
RNKi-molekula prema zahtjevu 1, naznačena time, da se sastoji od nukleotidne sekvence predstavljene sa SEQ ID NO:8.
R5, Ar1 and Ar2 groups are as defined above; under acidic or basic hydrolysis reaction conditions; 
[image] gdje R je alkil i R1, R2, R3, R4, R5, Ar1 i Ar2 skupine su kako je gore definirano; pod kiselim ili bazičnim uvjetima reakcije hidrolize;
The method of any of claims 1 to 16, further comprising the step of recrystallizing 3-(5-amino-2-methyl-4-oxoquinazolin-3(4 H)-yl)piperidine-2,6-dione hydrochloride; wherein optionally 3-(5-amino-2-methyl-4-oxoquinazolin-3(4 H)-yl)piperidine-2,6-dione hydrochloride has a purity no less than 95% by weight. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1 do 16, naznačen time što dodatno uključuje korak prekristaliziranja 3-(5-amino-2-metil-4-oksokinazolin-3(4H)-il)piperidin-2,6-dion-hidroklorida; gdje 3-(5-amino-2-metil-4-oksokinazolin-3(4H)-iI)piperidin-2,6-dion-hidroklorid može imati čistoću koja nije manja od 95%, težinski.
wherein the process is a compression- and compaction-free process. The capsule according to claim 1 wherein said drug substance is present as phosphate salt, preferably as mono-phosphate, more preferably as anhydrous mono-phosphate, even more preferably as anhydrous mono-phosphate salt in a polymorphic form characterized by an XRPD peak (2theta) at 15.0° ± 0.2°. 
Kapsula prema patentnom zahtjevu 1 naznačena time što je navedena supstanca lijeka prisutna kao fosfatna sol, poželjno kao monofosfat, poželjnije kao anhidrirani mono-fosfat, čak poželjnije kao anhidrirana mono-fosfatna sol u polimorfnom obliku naznačena time što je XRPD pik (2teta) na 15.0% £ 0.2".